ZA200807667B - Use of inhibitors of Jun N-terminal kinases to treat glaucoma - Google Patents
Use of inhibitors of Jun N-terminal kinases to treat glaucomaInfo
- Publication number
- ZA200807667B ZA200807667B ZA200807667A ZA200807667A ZA200807667B ZA 200807667 B ZA200807667 B ZA 200807667B ZA 200807667 A ZA200807667 A ZA 200807667A ZA 200807667 A ZA200807667 A ZA 200807667A ZA 200807667 B ZA200807667 B ZA 200807667B
- Authority
- ZA
- South Africa
- Prior art keywords
- jun
- inhibitors
- treat glaucoma
- terminal kinases
- kinases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/394,893 US7803824B2 (en) | 2004-10-29 | 2006-03-31 | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200807667B true ZA200807667B (en) | 2010-07-28 |
Family
ID=38523463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200807667A ZA200807667B (en) | 2006-03-31 | 2007-03-14 | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
Country Status (13)
Country | Link |
---|---|
US (3) | US7803824B2 (zh) |
EP (1) | EP2004158A2 (zh) |
JP (1) | JP5241033B2 (zh) |
KR (1) | KR20080108503A (zh) |
CN (1) | CN101415407B (zh) |
AR (1) | AR060222A1 (zh) |
AU (1) | AU2007235111B2 (zh) |
BR (1) | BRPI0710099A2 (zh) |
CA (1) | CA2644721A1 (zh) |
MX (1) | MX2008011319A (zh) |
TW (1) | TWI419694B (zh) |
WO (1) | WO2007117849A2 (zh) |
ZA (1) | ZA200807667B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
US20100056609A1 (en) * | 2008-08-26 | 2010-03-04 | Washington University | Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway |
US20120077753A1 (en) * | 2009-06-25 | 2012-03-29 | Laxman Gangwani | Jnk inhibitors for use in treating spinal muscular atrophy |
AU2012224653A1 (en) * | 2011-03-07 | 2013-10-03 | Fondazione Telethon | TFEB variants and uses thereof |
AU2014301631A1 (en) * | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
EP3160489B9 (en) * | 2014-06-26 | 2023-10-04 | Xigen Inflammation Ltd. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0840617B1 (en) * | 1996-04-26 | 2008-06-18 | University Of Ottawa | Use of naip or iap for the treatment and prevention of neuronal disease |
US6451787B1 (en) * | 1998-10-13 | 2002-09-17 | Cephalon, Inc. | Remedies for ocular diseases |
ES2209527T3 (es) | 1998-12-17 | 2004-06-16 | F. Hoffmann-La Roche Ag | "44- y 5-alquiniloxindolels y 4- y 5-alqueniloxindones. |
WO2000064872A1 (en) | 1999-04-23 | 2000-11-02 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
DE60039616D1 (de) | 1999-08-13 | 2008-09-04 | Vertex Pharma | INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN |
NZ517578A (en) | 1999-08-19 | 2004-02-27 | Signal Pharm Inc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions |
US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
EP1088815A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
EP1088822A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl hydrazide derivatives |
EP1088821A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
EP1110957A1 (en) | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
JP2003535062A (ja) | 2000-06-01 | 2003-11-25 | メルク エンド カムパニー インコーポレーテッド | Jnk阻害剤としての(二置換フェニル)ピリミジニルイミダゾール誘導体の使用 |
EP1193256A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
EP1364949A4 (en) | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | INHIBITOR OF JNK |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
US6982274B2 (en) | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
US20040254189A1 (en) | 2001-08-23 | 2004-12-16 | Hideaki Nagaya | Jnk inhibitors |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
JP2003129190A (ja) | 2001-10-19 | 2003-05-08 | Sumitomo Metal Ind Ltd | マルテンサイト系ステンレス鋼およびその製造方法 |
US20030138819A1 (en) | 2001-10-26 | 2003-07-24 | Haiqing Gong | Method for detecting disease |
US7390797B2 (en) * | 2002-02-28 | 2008-06-24 | Eisai Co., Ltd. | Fused indazole compounds |
MXPA04009471A (es) * | 2002-04-30 | 2005-01-25 | Alcon Inc | Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas. |
JP4662764B2 (ja) | 2002-06-14 | 2011-03-30 | メルク セローノ ソシエテ アノニム | アゾールメチリデンシアニド誘導体およびそれらのタンパク質キナーゼモジュレーターとしての使用 |
KR20050057175A (ko) * | 2002-09-20 | 2005-06-16 | 알콘, 인코퍼레이티드 | 안구건조증 치료용 사이토카인 합성 저해제의 용도 |
US20040092568A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
US20060275797A1 (en) * | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
-
2006
- 2006-03-31 US US11/394,893 patent/US7803824B2/en not_active Expired - Fee Related
-
2007
- 2007-03-14 EP EP07758510A patent/EP2004158A2/en not_active Withdrawn
- 2007-03-14 CA CA002644721A patent/CA2644721A1/en not_active Abandoned
- 2007-03-14 WO PCT/US2007/063961 patent/WO2007117849A2/en active Application Filing
- 2007-03-14 ZA ZA200807667A patent/ZA200807667B/xx unknown
- 2007-03-14 AU AU2007235111A patent/AU2007235111B2/en not_active Ceased
- 2007-03-14 KR KR1020087023895A patent/KR20080108503A/ko not_active Application Discontinuation
- 2007-03-14 CN CN2007800116928A patent/CN101415407B/zh not_active Expired - Fee Related
- 2007-03-14 BR BRPI0710099-0A patent/BRPI0710099A2/pt not_active IP Right Cessation
- 2007-03-14 MX MX2008011319A patent/MX2008011319A/es active IP Right Grant
- 2007-03-14 JP JP2009503137A patent/JP5241033B2/ja not_active Expired - Fee Related
- 2007-03-19 TW TW096109322A patent/TWI419694B/zh not_active IP Right Cessation
- 2007-03-29 AR ARP070101334A patent/AR060222A1/es not_active Application Discontinuation
-
2010
- 2010-08-18 US US12/858,739 patent/US20100311716A1/en not_active Abandoned
-
2011
- 2011-09-14 US US13/232,410 patent/US20120004274A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7803824B2 (en) | 2010-09-28 |
EP2004158A2 (en) | 2008-12-24 |
AU2007235111B2 (en) | 2012-03-22 |
US20060172991A1 (en) | 2006-08-03 |
MX2008011319A (es) | 2008-09-19 |
TWI419694B (zh) | 2013-12-21 |
TW200744601A (en) | 2007-12-16 |
WO2007117849A3 (en) | 2008-04-10 |
CA2644721A1 (en) | 2007-10-18 |
AU2007235111A1 (en) | 2007-10-18 |
CN101415407A (zh) | 2009-04-22 |
AR060222A1 (es) | 2008-06-04 |
JP5241033B2 (ja) | 2013-07-17 |
KR20080108503A (ko) | 2008-12-15 |
US20100311716A1 (en) | 2010-12-09 |
JP2009532373A (ja) | 2009-09-10 |
CN101415407B (zh) | 2011-05-11 |
US20120004274A1 (en) | 2012-01-05 |
BRPI0710099A2 (pt) | 2011-08-02 |
WO2007117849A2 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263237A (en) | Use of complement pathway inhibitors to treat eye diseases | |
HK1226071A1 (zh) | 激酶抑制劑的組合物及其在治療癌症與其與激酶相關的疾病中的用途 | |
EP2026843A4 (en) | THERAPEUTIC USES OF RTP801L INHIBITORS | |
IL207609A0 (en) | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases | |
IL232786A0 (en) | Inhibitors of e1 enzyme activators | |
HK1167655A1 (zh) | -末端激酶抑制劑 | |
IL208719A0 (en) | Inhibitors of protein kinases | |
ZA200807667B (en) | Use of inhibitors of Jun N-terminal kinases to treat glaucoma | |
EP2278969A4 (en) | INHIBITORS OF JANUS KINASES | |
EP1981888A4 (en) | TYROSINE KINASE INHIBITORS AND USES THEREOF | |
HK1160607A1 (zh) | 用於治療乾眼症和其它與眼相關疾病的 激酶 | |
IL211835A0 (en) | Therapeutic uses of inhibitors of rtp801 | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
EP2310384A4 (en) | INHIBITORS OF KINASES JANUS | |
EP2341775A4 (en) | INHIBITORS OF JANUS KINASES | |
EP2323659A4 (en) | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | |
EP2242501A4 (en) | THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE | |
IL195722A0 (en) | Therapeutic uses of inhibitors of rtp801l |